Corticosteroid-Associated Avascular Necrosis of the Femoral Head in Patients with Severe COVID-19: A Single-Center Study

Vensan Velchov; Pavel Georgiev; Stefan Tserovski; Tsvetan Tsenkov; Venelin Alexiev

doi:10.12659/MSM.940965

11 July 2023 : Clinical Research

Corticosteroid-Associated Avascular Necrosis of the Femoral Head in Patients with Severe COVID-19: A Single-Center Study

Vensan Velchov^12ABCDE*, Pavel Georgiev^12ABCG, Stefan Tserovski^12DEFG, Tsvetan Tsenkov

^12AEFG, Venelin Alexiev^12ACDEF

DOI: 10.12659/MSM.940965

Med Sci Monit 2023; 29:e940965

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Summarized demographic and COVID-19-related patient data.

Initials	Sex	Age	Therapy	COVID-19	COVID-19 treatment duration	Days till AVN onset	D-dimer (μg/ml)	CRP (mg/L)	Orthopedic treatment
P.K.T.	M	60	3×40 mg Methylprednisolone + 2×4 mg Dexamethasone	Severe	7–30 days	60	0.36	26	THA
Y.G.A.	M	59	2×40 mg Methylprednisolone	Severe	7–30 days	55	0.41	33	THA
S.B.S.	M	49	3×40 mg Methylprednisolone + 2×4 mg Dexamethasone	Severe	7–30 days	57	1.1	42	THA + CDS
O.D.P.	F	68	2×4 mg Dexamethasone	Moderate	14 days	66		27	THA
R.P.S.	M	44	2×4 mg Dexamethasone	Moderate	14 days	46		25	THA
M.D.P.	M	57	2×4 mg De×amathasone	Moderate	21 days	59		30	THA
A.H.D.	M	68	2×40 mg Methylprednisolone + 2×4 mg Dexamethasone	Severe	21 days	65	0.29	25	THA
W.G.P.	M	49	2× 4 mg Dexamethasone	Moderate	21 days	58		24	THA
L.D.K.	M	61	2×4 mg Dexamethasone	Severe	21 days	65	0.32	24	THA
D.D.C.	M	57	2×4 mg Dexamethasone	Moderate	21 days	59		33	THA
A.H.K.	F	51	2×40 mg Methylprednisolone + 2×4 mg Dexamethasone	Severe	14–30 days	48	0.35	34	THA
L.H.G.	F	67	2×40 mg Methylprednisolone + 2×4 mg Dexamethasone	Severe	14–30 days	69	0.37	26	THA
P.D.T.	M	58	2×4 mg Dexamethasone	Severe	21 days	60	0.3	24	CDS
M.G.H.	M	39	3×40 mg Methylprednisolone + 2×4 mg Dexamethasone	Severe	14–30 days	47	0.4	30	THA
L.K.Y.	F	68	2×40 mg Methylprednisolone+ 2×4 mg Dexamethasone	Severe	7–30 days	65	0.44	31	THA
P.D.M.	M	49	3×40 mg Methylprednisolone +2×4 mg Dexamethasone	Severe	14–30 days	49	0.34	34	THA + CDS
S.D.B.	M	53	2×40 mg Methylprednisolone	Severe	14–30 days	60	0.41	36	THA
G.I.B.	F	61	2×4 mg Dexamethasone	Moderate	21 days	57		30	THA
S.I.L.	F	43	2×40 mg Methylprednisolone	Severe	7–30 days	49	0.32	38	THA
Y.Y.G.	M	49	2×40 mg Methylprednisolone	Severe	14–30 days	51	0.44	36	THA + CDS
P.G.H.	M	57	2×40 mg Methylprednisolone	Severe	14–30 days	62	0.29	32	THA
S.I.S.	M	60	2×4 mg Dexamethasone	Moderate	21 days	55		35	THA
I.G.I.	F	51	2×4 mg Dexamethasone	Moderate	21 days	50		24	THA
P.Y.P.	M	57	2×40 mg Methylprednisolone	Severe	14–30 days	61	0.45	34	THA + CDS

Back to the Article

Corticosteroid-Associated Avascular Necrosis of the Femoral Head in Patients with Severe COVID-19: A Single-Center Study

Your Privacy